SCHEMBL3316663

SCHEMBL3316663

CCN(C)CCCNC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25004071 0.95 PRMT3 (0.40)
SCHEMBL22343848 0.92 EPHX1 (0.46)
SCHEMBL16475529 0.90 EPHX1 (0.44)
SCHEMBL22564674 0.90 EPHX1 (0.50)
SCHEMBL19245115 0.90 EPHX1 (0.50)
SCHEMBL13856009 0.90 EPHX1 (0.44)
SCHEMBL17001500 0.90 EPHX1 (0.50)
SCHEMBL1231390 0.86 PRMT3 (0.50)
SCHEMBL17804601 0.85 PRMT3 (0.46)
SCHEMBL10045279 0.83 PRMT3 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3596075-B1 AZAINDOLES AS INHIBITORS OF HPK1 HOFFMANN LA ROCHE (CH) 2023-10-11 EP disclosed
WO-2023073600-A1 COMPOSITIONS FOR PREVENTING OR TREATING IDIOPATHIC PULMONARY FIBROSIS (IPF) CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2023-05-04 WO disclosed
WO-2023066190-A1 COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) 2023-04-27 WO disclosed
US-11472807-B2 Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) 2022-10-18 US disclosed
US-20220296594-A1 POTENTIATORS OF ANTIMICROBIAL AND/OR ANTIVIRAL AGENTS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2022-09-22 US disclosed
EP-2087910-B1 Polymeric prodrugs ASCENDIS PHARMA GMBH (DE) 2022-05-04 EP disclosed
EP-2087910-B1 Polymeric prodrugs ASCENDIS PHARMA GMBH (DE) 2022-05-04 EP disclosed
US-20210283264-A1 Polymeric Prodrugs with a Self-Immolative Linker ASCENDIS PHARMA GMBH (DE) 2021-09-16 US disclosed
US-20210283264-A1 Polymeric Prodrugs with a Self-Immolative Linker ASCENDIS PHARMA GMBH (DE) 2021-09-16 US disclosed
EP-3600307-B1 COMPOSITIONS FOR USE IN METHODS OF INHIBITING PROTEIN KINASES UNIV HOUSTON SYSTEM (US) 2021-05-05 EP disclosed
EP-1485377-B1 PYRANONES USEFUL AS ATM INHIBITORS KUDOS PHARM LTD (GB) 2009-12-09 EP disclosed
EP-2087910-A2 Polymeric prodrugs Complex Biosystems GmbH (DE) 2009-08-12 EP disclosed
EP-2087910-A2 Polymeric prodrugs Complex Biosystems GmbH (DE) 2009-08-12 EP disclosed
US-20080241102-A1 Polymeric Prodrug with a Self-Immolative Linker COMPLEX BIOSYSTEMS GMBH (DE) 2008-10-02 US disclosed
US-20080241102-A1 Polymeric Prodrug with a Self-Immolative Linker COMPLEX BIOSYSTEMS GMBH (DE) 2008-10-02 US disclosed
US-20080241102-A1 Polymeric Prodrug with a Self-Immolative Linker COMPLEX BIOSYSTEMS GMBH (DE) 2008-10-02 US disclosed
EP-1463733-B1 MITOTIC KINESIN INHIBITORS MERCK & CO INC (US) 2007-09-05 EP disclosed
US-20070037834-A1 Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection KYOWA HAKKO KIRIN CO., LTD. (JP) 2007-02-15 US disclosed
EP-0422858-A2 Multifunctional viscosity index improver EXXON CHEMICAL PATENTS INC. (US) 1991-04-17 EP disclosed
US-4291150-A INTERFACIAL POLYMERIZATION GENERAL ELECTRIC CO. (US) 1981-09-22 US disclosed